These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12387050)

  • 21. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
    Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular effects of sulphonylureas: role of K(ATP) channels.
    Howes LG
    Diabetes Obes Metab; 2000 Apr; 2(2):67-73. PubMed ID: 11220526
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.
    Louchami K; Ladrière L; Jijakli H; Malaisse WJ
    Endocrine; 1998 Jun; 8(3):247-50. PubMed ID: 9741829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Regulation of ATP-dependent potassium channels].
    De Weille JR; Schmid-Antomarchi H; Fosset M; Lazdunski M
    Journ Annu Diabetol Hotel Dieu; 1991; ():119-24. PubMed ID: 1715929
    [No Abstract]   [Full Text] [Related]  

  • 26. Repaglinide and related hypoglycemic benzoic acid derivatives.
    Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
    J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
    Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
    Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Flexible oral therapy of diabetes mellitus type 2: dietary glucose regulation as therapeutic principle. 34th annual session of the European Association for the Study of Diabetes (EASD). Barcelona, 8-12 September 1998].
    Dtsch Med Wochenschr; 1998 Dec; 123(50 Suppl Flexible):1-4. PubMed ID: 9883267
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repaglinide dose response? A clinician's viewpoint.
    Strange P; Goldberg RB
    Diabetes Technol Ther; 2000; 2(1):119-21. PubMed ID: 11467310
    [No Abstract]   [Full Text] [Related]  

  • 32. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.
    Ozbek M; Erdogan M; Karadeniz M; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C; Tuzun M
    Acta Diabetol; 2006 Dec; 43(4):148-51. PubMed ID: 17211567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
    Ambavane V; Patil R; Ainapure SS
    J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
    [No Abstract]   [Full Text] [Related]  

  • 34. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R
    Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Structure and action mechanism of sulfonylurea].
    Tasaka Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():333-8. PubMed ID: 12387014
    [No Abstract]   [Full Text] [Related]  

  • 39. [Ion channel mechanisms in insulin secretion].
    Kakei M; Koriyama N; Nakata M; Dezaki K; Yada T
    Nihon Rinsho; 2002 Jul; 60 Suppl 7():180-9. PubMed ID: 12238045
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
    Scheen AJ
    Rev Med Liege; 2001 Jun; 56(6):456-9. PubMed ID: 11496727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.